KYMR Earnings Prediction
The chart below shows how KYMR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, KYMR sees a -0.04% change in stock price 10 days leading up to the earnings, and a +6.13% change 10 days following the report. On the earnings day itself, the stock moves by -0.21%. This data can give you a slight idea of what to expect for the next quarter's release.
KYMR Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
7.39M
-84.56%
97.65%
Gross Margin
--
--
--
Operating Margin
-1092.17%
2608.08%
-43.35%
Net Margin
-956.88%
3088.54%
-42.71%
EPS
-0.88
-252.00%
7.32%
No Data Available
KYMR Earnings Analysis
Kymera Therapeutics Inc Corporation (KYMR.O) Earnings Conference Call
Positive
Phase I Study Initiation: Kymera Therapeutics successfully completed IND-enabling studies for KT-621 and initiated a Phase I healthy volunteer study, marking the first STAT6 targeted agent to enter clinical development.
Phase I Data and Studies: The company is on track to report KT-621 Phase I data in June 2025 and initiate two Phase 2b studies in atopic dermatitis and asthma in 2025 and 2026, respectively.
TYK2 Program Advancement: Kymera has advanced its TYK2 program with the development candidate KT-295, which is expected to enter the clinic next quarter, with Phase 1 data anticipated by year-end 2025.
IRAK4 Development Acceleration: The partnership with Sanofi has led to the expansion of Phase IIb studies for IRAK4, accelerating the development timeline towards pivotal trials.
Cash Balance and Runway: Kymera's cash balance of $851 million at the end of 2024 provides a runway into mid-2027, allowing for the execution of multiple data readouts and important Phase II trials.
New Immunology Program Launch: The company plans to unveil a new immunology program in May 2025, which aligns with its strategy to develop innovative oral small molecule therapies.
Negative
Limited Revenue Diversification: Revenue in Q4 2024 was only $7.4 million, entirely from the Sanofi collaboration, indicating limited diversification in revenue streams.
R&D Expense Concerns: R&D expenses for the quarter were $71.8 million, with a significant portion being non-cash stock-based compensation, raising concerns about actual cash burn.
R&D Spending Increase: Adjusted cash R&D spend increased by 23% sequentially, suggesting rising costs without corresponding revenue growth.
Rising G&A Expenses: G&A expenses also rose by 13% sequentially, indicating increasing operational costs that may not be sustainable in the long term.
Partnership Revenue Dependency: The company is heavily reliant on its partnership with Sanofi for revenue, which may pose risks if the collaboration does not yield expected results.
Phase II Trial Uncertainty: The Phase II trials for KT-621 and KT-295 are still in early stages, and there is uncertainty regarding their success and market acceptance.
Phase III Study Delays: The timeline for pivotal Phase III studies has been pushed to 2026, indicating potential delays in bringing products to market.
KYMR FAQs
How does KYMR typically perform around its earnings report dates?
Is Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
KYMR Earning Call Sentiment
Kymera Therapeutics, Inc. (KYMR) Q4 2024 Earnings Call Transcript
KYMR.O
-2.02%Positive
The earnings call summary shows a mixed sentiment: strong financial health with a cash runway until mid-2027 and strategic focus on immunology. However, the low revenue, high R&D expenses, and competitive pressures in the immunology space present concerns. The Q&A highlights confidence in clinical trials but also reveals management's evasiveness on certain details, adding uncertainty. The market cap suggests moderate stock movement, leading to a neutral prediction.
